| Literature DB >> 34461917 |
Taniela Bes1,2, Debora Nagano3, Roberta Martins3, Ana Paula Marchi3, Lauro Perdigão-Neto4,3,5, Hermes Higashino4, Gladys Prado3, Thais Guimaraes4,5, Anna S Levin4,3,5, Silvia Costa4,3,5.
Abstract
Carbapenem-resistant Enterobacteriaceae are a worldwide health problem and isolates carrying both blaKPC-2 and blaNDM-1 are unusual. Here we describe the microbiological and clinical characteristics of five cases of bloodstream infections (BSI) caused by carbapenem-resistant Klebsiella pneumoniae and Serratia marcescens having both blaKPC-2 and blaNDM-1. Of the five blood samples, three are from hematopoietic stem cell transplantation patients, one from a renal transplant patient, and one from a surgical patient. All patients lived in low-income neighbourhoods and had no travel history. Despite antibiotic treatment, four out of five patients died. The phenotypic susceptibility assays showed that meropenem with the addition of either EDTA, phenylboronic acid (PBA), or both, increased the zone of inhibition in comparison to meropenem alone. Molecular tests showed the presence of blaKPC-2 and blaNDM-1 genes. K. pneumoniae isolates were assigned to ST258 or ST340 by whole genome sequencing. This case-series showed a high mortality among patients with BSI caused by Enterobacteriae harbouring both carbapenemases. The detection of carbapenemase-producing isolates carrying both blaKPC-2 and blaNDM-1 remains a challenge when using only phenotypic assays. Microbiology laboratories must be alert for K. pneumoniae isolates producing both KPC-2 and NDM-1.Entities:
Keywords: Carbapenem resistance; Carbapenemases; Enterobacteriaceae; bla KPC-2; bla NDM-1
Mesh:
Substances:
Year: 2021 PMID: 34461917 PMCID: PMC8404334 DOI: 10.1186/s12941-021-00464-5
Source DB: PubMed Journal: Ann Clin Microbiol Antimicrob ISSN: 1476-0711 Impact factor: 3.944
Fig. 1Phylogenies of K. pneumoniae showing the same clone ST340 in the BMT unit and the globally disseminated, ST258 in Renal Transplant Unit
Underlying clinical conditions, antibiotic therapy, outcome, and phenotypic analyze
| Isolate ID | Underlying clinical condition | Impiric treatment | Culture guided added tratment | Outcome | Phenotypic Tests—Serina-β-lactamases (DD mm) | Phenotypic Tests—MBLs (DD mm) | Carbapenem-bac |
|---|---|---|---|---|---|---|---|
ST340 | Leukocytes: 100 Neutrophils: 0 Allogeneic BMT (10/11/2012) | Meropenem | Tigecycline Colistin | Death 2 days after blood positive culture | IMP: 0 ERT: 0 MPM: 0 MPM + PBA: 14 mm MPM + EDTA + PBA: 17 mm | IMP: 0 ERT: 0 MPM: 0 MPM + EDTA: 0 (phantom zone 14) MPM + EDTA + PBA: 17 mm | Positive |
12/14/2012 ST340 | Neutrophils: 0 Not related allogeneic TCTH (12/09/2012) | Meropenem | Tigecycline Colistin | Death 2 days after blood positive culture | IMP: 23 mm ERT: 16 mm MPM: 20 mm MPM + PBA: 23 mm MPM + EDTA + PBA: 23 mm | IMP: 23 mm ERT: 16 mm MPM: 20 mm MPM + EDTA: 21 mm MPM + EDTA + PBA: 23 mm | Positive |
ST340 | Cefepime | Tigecycline Colistin | Discharge from hospital 23 days after blood positive culture, for a total of 64 days hospitalization | IMP: 0 ERT: 0 MPM: 0 MPM + PBA: 13 mm MPM + EDTA + PBA: 18 mm | IMP: 0 ERT: 0 MPM: 0 MPM + EDTA: 10 (phantom zone 14) MPM + EDTA + PBA: 18 mm | Positive | |
6/14/2013 | Ciprofloxacin Clindamycin | Tigecycline Fosfomycin | Death 11 days after blood positive culture | IMP: 13 mm ERT: 17 mm MPM: 23 mm MPM + PBA: 25 mm MPM + EDTA + PBA: 26 mm | IMP: 13 mm ERT: 17 mm MPM: 23 mm MPM + EDTA: 19 mm MPM + EDTA + PBA: 26 mm | Positive | |
10/21/16 ST258 | Urinary tract infection (10/20/16) Graft Nephrectomy (11/23/16) | Meropenem | Ceftazidime + Avibactam | Death 40 days after blood positive culture | IMP: 6 mm ERT: 0 MPM: 0 (phantom zone 7 mm) MPM + PBA: 14 mm MPM + EDTA + PBA: 16 mm (phantom zone 20) | IMP: 6 mm ERT: 0 MPM: 0 (phantom zone 7 mm) MPM + EDTA: 9 mm (phantom zone 20) MPM + EDTA + PBA: 16 mm (phantom zone 20) | Positive |
MPM Meropenem, IMP Imipenem, ERT Ertapenem, PBA Phenylboronic Acid, DD Diffusion Disk, MLST Multilocus sequence typing
Minimal inhibitory concentration, virulence and resistance-associated genes identified by whole genome sequence
| Isolate | Beta-Lactams’ resistance | Aztreonam (MIC) | Meropenem (MIC) | Imipenem (MIC) | Ceftazidime (MIC) | DD Ceftazidime Avibactam | Aminoglycosides resistance genes | Amikacin (MIC) | Colistin (MIC) | Tigecycline (MIC) | Quinolone resistance genes | Ciprofloxacin (MIC) | Virulence genes adherence | Virulence gene efflux pump | Virulence gene iron acquisition |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| blaCTX-M-15 blaKPC-2 blaSHV-11 blaTEM-1B | ≥ 32 [R] | ≥ 16 [R] | ≥ 16 [R] | ≥ 16 [R] | 25 mm [S] | aac (3)-Iia aac(6′)Ib-cr aadA2 strA strB | < 4 [S] | 4 | 0.5 | aac (6')Ib-cr oqxA oqxB QnrB1 | ≥ 4 [R] | mrkA/B/C/D/F/H/I/J filmA/B/C/D/E/F/G/H/I/K | acrA/B | iutA entA/B/C/D/E/F/S fepA/B/C/D/G iroE/N | |
| blaKPC-2 blaSHV-11 | ≥ 32 [R] | 4 [R] | 2 | 16 [R] | 24 mm [S] | aph (3′)-Ia aadA2 | 8 | ≥ 4 [R] | 0.5 | oqxA oqxB | ≥ 4 [R] | mrkC/H/I/J filmA/B/D/E/G/H/I | acrA/B | entA/B/C fepB/G iroN | |
| blaKPC-2 blaSHV-5 blaSRT-2 | ≥ 32 [R] | ≥ 16 [R] | ≥ 16 [R] | ≥ 16 [R] | 30 mm [S] | Aph(3′)-Via | 16 | 0,5 | 0.5 | OqxA oqxB fosA dfrA14 | ≥ 4 [R] | mrkA/B/C/D/F/H/I/J filmA/B/C/D/E/F/G/H/I/K | acrA/B | iutA entA/B/C/D/E/F/S fepA/B/C/D/G iroE/N | |
| blaKPC-2 blaSHV-5 blaSRT-2 | ≥ 32 [R] | 4 [R] | 8 | ≥ 16 [R] | 24 mm [S] | aacA4 aac(6′)-Ic aadB | 16 | ≥ 4 [R] | 2 | aac(6′)-Ib-cr | ≥ 4 [R] | shlA/B rssA/B | |||
| blaCTX-M-14 blaKPC-2 blaSHV-11 blaTEM-1B | ≥ 32 [R] | ≥ 64[R] | ≥ 16 [R] | ≥ 16 [R] | 23 mm [S] | rmtB aac(3)-Iid aph(3′)-Ia aadA2 aph(6)-Id aph(3′′)-Ib | ≥ 64 [R] | 2 | 0.5 | oqxA oqxB | ≥ 4 [R] | mrkA/B/C/D/F/H/I/J filmA/B/C/D/E/F/G/H/I/K | acrA/B | iutA entA/B/C/D/E/F/S fepA/B/C/D/G iroE/N |
MLST Multilocus sequence typing, R Resistant, S Susceptible, MIC Minimum inhibitory concentrations, DD Diffusion Disc